Mursla Bio

Mursla Bio is a pioneering biotech company on a mission to transform cancer care by pushing the boundaries of biopsy technology. Its breakthrough dynamic biopsy platform combines the strengths of both tissue and liquid biopsies without their limitations in invasiness or biological insights. Dynamic biopsy is made possible by coupling the latest of extracellular vesicle (EV) and extracellular omics science with Mursla Bios pioneering EV technologies. Mursla Bios initial focus is to transform the surveillance of liver cancer in high-risk populations - the fastest growing cause of cancer related deaths. Mursla Bio is currently conducting a multi-center clinical study to...

Biotech,cancer,diagnostics,proteomics,biomarker,liquid biopsy,oncology,extracellular vesicle,techbio,biology,transcriptomics,computational biology,and liver

Mursla bio operates in the Biotechnology research industry.

Mursla bio's revenue is 11m - 100m

Mursla bio has 11 - 50 employees.